This study by Chiang et al. addresses a hot topic in the field i.e. SARS-COV-2 infection within the asthmatic children and the outcomes of the disease. The authors aimed to assess whether the use of asthma medicines was associated with clinical manifestations and outcomes of infection with SARS-CoV-2 among children with asthma. The study first defined the characteristics of the study population and the clinical symptom severity among the infected children. Then the risk factors associated with being symptomatic, SARS-COV-2 disease severity, hospitalization rates were evaluated. Finally the effect of asthma medications on SARS-COV-2 disease severity and the need for a change in asthma medications following SARS-COV-2 were documented. In general the paper is well written and discussed. However there are some questions need to be answered for the clarity of the study as well as some minor concerns to be addressed. You can see my comments below:
Major:
1. Why did the researchers used only reverse transcription polymerase chain reaction (RT-PCR) tests and, not the serum-specific antibodies against 2019-nCoV as well, for the confirmation of the disease. As the sensitivity of these tests are limited probably some SARS-CoV-2 patients were missed. What is the definition of asthma exacerbation? Did the researchers used GINA guideline for this or not? Please clarify within the methods section.
2. In the study there is an asthma exacerbation rate of 22.5%. Is this frequency higher that the expected number in an asthmatic child population without SRAS-COV-2 in that particular time of the year. Could you please discuss this data in the discussion section.
3. Discussion section lines 239-242 “A higher proportion of those who used inhaled bronchodilators were symptomatic, likely because their asthma was more severe than those who did not. Of note is that those who used ICS or a combined inhaler were not more likely to be symptomatic than those who did not.”
How can the authors make a conclusion as mentioned above? This reviewer thinks that the control status of the asthma rather than the severity of the disease seems to be more important with these findings? Could you comment on this in the discussion section ?
4. What about the radiologic findings of the patients? Could you please give some information about the chest X rays and if applied the CT scans of the children? What was the pneumonia rate among the hospitalized children?
5. What is the median follow up time of the patients as there is a data given about the sequela of the patients in Table 2? If I understand right this data is just for acute sequela and not considering the chronic ones.

In this revision authors made changes and improvements in the manuscript and they included some missing data to increase the quality of the paper. Im satisfied with the answers and replies to my questions.